12-Month Lobbying Summary - In-house Corporation

• Subject matter details in previous versions

  Details Regarding the Identified Subject Matter

  Subject matters	Details	Categories
  Subject matters were not required to be associated with subject matter details when this content was submitted	Common Drug Review, as it relates to health technology assessments and drug product reimbursement recommendations.	Politique ou Programme
  Subject matters were not required to be associated with subject matter details when this content was submitted	Communicating with government officials about the Pan-Canadian Health Data Strategy, more specifically about health data foundations.	Politique ou Programme
  Subject matters were not required to be associated with subject matter details when this content was submitted	Establishment of Canadian Drug Agency and National Formulary	Politique ou Programme
  Subject matters were not required to be associated with subject matter details when this content was submitted	Federal Life Sciences/ Biomanufacturing Strategy	Politique ou Programme
  Subject matters were not required to be associated with subject matter details when this content was submitted	Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.	Politique ou Programme
  Subject matters were not required to be associated with subject matter details when this content was submitted	Food and Drugs Act Modernization initiative, as it relates to reform of drug submission review and approval process.	Politique ou Programme, Proposition législative, Projet de loi ou résolution, Règlement
  Subject matters were not required to be associated with subject matter details when this content was submitted	Food and Drugs Act and Regulations, as they relate to drug export and cross-border trade.	Proposition législative, Projet de loi ou résolution, Règlement
  Subject matters were not required to be associated with subject matter details when this content was submitted	Food and Drugs Act and Regulations, as they relate to the establishment of an approval framework for subsequent entry biologic products.	Proposition législative, Projet de loi ou résolution, Règlement
  Subject matters were not required to be associated with subject matter details when this content was submitted	Food and Drugs Act and Regulations, as they relate to the provision of data exclusivity for innovative drug products.	Proposition législative, Projet de loi ou résolution, Règlement
  Subject matters were not required to be associated with subject matter details when this content was submitted	Food and Drugs Act and Regulations, as they relate to the review and approval of new drug submissions and post market surveillance of drug products.	Proposition législative, Projet de loi ou résolution, Règlement
  Subject matters were not required to be associated with subject matter details when this content was submitted	Industry Canada Advantage Canada and Science and Technology Strategies, or other Government policy or program initiatives to support research and development activities in Canada.	Politique ou Programme
  Subject matters were not required to be associated with subject matter details when this content was submitted	National Pharmaceutical Strategy, as it relates to enhanced access to orphan drugs and incentives for development of the treatments for rare disorders.	Politique ou Programme
  Subject matters were not required to be associated with subject matter details when this content was submitted	Patent Act and Patented Medicines (Notice of Compliance) Regulations, as it relates to the regulation of intellectual property and approval for therapeutic products.	Proposition législative, Projet de loi ou résolution, Règlement
  Subject matters were not required to be associated with subject matter details when this content was submitted	Patented Medicine Prices Review Board (PMPRB), as it relates to implementation timeframe, pricing, guidelines, reporting requirements and dispute resolution.	Proposition législative, Projet de loi ou résolution, Règlement
  Subject matters were not required to be associated with subject matter details when this content was submitted	Patented Medicine Prices Review Board (PMPRB), as it relates to pricing guidelines.	Politique ou Programme

  Subject matters in previous versions

  • International Trade
  • Taxation and Finance
  • Industry
  • Intellectual Property
  • Research and Development
  • Health
  • Science and Technology

Government Institutions

• Global Affairs Canada (GAC)
• Federal Economic Development Agency for Southern Ontario (FedDev)
• Veterans Affairs Canada (VAC)
• Privy Council Office (PCO)
• Prime Minister's Office (PMO)
• House of Commons
• Patented Medicine Prices Review Board (PMPRB)
• Pacific Economic Development Canada (PacifiCan)
• Employment and Social Development Canada (ESDC)
• Finance Canada (FIN)
• Innovation, Science and Economic Development Canada (ISED)
• Canadian Institutes of Health Research (CIHR)
• Invest in Canada Hub
• Health Canada (HC)
• Treasury Board Of Canada Secretariat (TBS)
• Senate of Canada

Communication techniques

Communication techniques that have been used or are expected to be used in the course of the undertaking:

• Written communication
• Oral communication
• Arrange one or more meetings

Senior Officers whose lobbying activities represent less than 20% of their Duties

• Ugur Gunaydin, General Manager, Canada | No public offices held
• John Brenton, Senior Manager, Value Access and Policy | No public offices held
• John Snowden, Executive Director, Value, Access and Policy | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

• Angela Behboodi, Government Affairs Director | Public offices held